Opus Genetics (IRD) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Opus Genetics (IRD) overview

Opus Genetics (IRD) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 14.2m and operating profit of USD -38.6m; the year-end share price was 2.01 USD and market capitalisation was USD 140m. Opus Genetics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Opus Genetics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 15.3mFY 2025
Share price2.01 USDFY 2025 year end
RevenueUSD 14.2mFY 2025
Operating profitUSD -38.6mFY 2025
Net earningsUSD -49.6mFY 2025
Market capitalisationUSD 140mFY 2025 year end

About Opus Genetics

Opus Genetics develops gene therapies for inherited retinal diseases and other therapies for ophthalmic disorders. Its pipeline includes adeno-associated virus programs targeting genetic causes of retinal degeneration, including LCA5 and BEST1-related conditions. The company is also advancing phentolamine ophthalmic solution, which is approved for pharmacologically induced mydriasis and is being evaluated for additional eye-related indications. Its gene therapies are administered by subretinal injection.

Generate the Opus Genetics report

Opus Genetics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Opus Genetics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Opus Genetics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.